New second generation solvent evaporators from Biotage
Three new TurboVap evaporation systems increase laboratory reliability.
Biotage has launched three new TurboVap evaporation systems - second generation systems, which build upon the solid foundations of the historic TurboVap product line.
The new TurboVap LV, II and EH systems incorporate many new customer driven features and enable end users to switch quickly between the functionality they are presently accustomed to in the classic instruments. Each system has enhanced visibility, a compact design, removable/adjustable nozzles, exchangeable manifolds, evaporation flow gradients, and a touch screen interface.
The TurboVap EH system is seamlessly integrated with the Biotage Extrahera and is aesthetically very similar, with similar internal lighting, glass sides and a glass lid, greatly improving sample visibility. In parallel, Biotage are introducing a series of Multi-Racks that offer greater flexibility in the variety of different tube and vial sizes that can be processed. Each system of course still has the highly efficient patented gas vortex shearing technology, which is synonymous with the TurboVap brand.
“Our new TurboVap enhanced evaporation systems, are built on the reliability and performance associated with the TurboVap name. The new systems will increase laboratory efficiency, improve the cost of analysis and enable improved user control of the evaporation process” said Mr Paul Roberts, Global Product Manager, Analytical Consumables and Systems, Biotage.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.